Age is a predictor of efficacy of monoclonal antibodies in allergic severe asthma Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019
Determining early response to anti-IL5/IL5R monoclonal antibodies in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020
Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005
Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021
The Dutch hypothesis, implications for treatment of chronic obstructive pulmonary disease and asthma in a biomarker, monoclonal antibody world. Experience with IgE and omalizumab in a small pulmonary practice Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Two novel, severe asthma phenotypes identified during childhood using a clustering approach Source: Eur Respir J 2012; 40: 55-60 Year: 2012
Antinuclear antibodies and rheumatoid factor are associated with blood eosinophils in asthma and COPD Source: International Congress 2016 – Immune responses in the lung Year: 2016
Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma Source: ERJ Open Res, 7 (3) 00190-2021; 10.1183/23120541.00190-2021 Year: 2021
Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005
Relationship between benralizumab exposure and asthma exacerbation rate for patients with severe asthma Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017
Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021
Evaluation and management of difficult-to-control asthma Source: Annual Congress 2007 - PG1 - Asthma: from bench to bedside Year: 2007
Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011
The immunological features of the severe steroid-resistant asthma Source: Eur Respir J 2003; 22: Suppl. 45, 479s Year: 2003
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena Source: Eur Respir J, 56 (4) 2000117; 10.1183/13993003.00117-2020 Year: 2020
Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021
Characteristics, definition and phenotypes of severe asthma Source: Eur Respir Mon 2011; 51: 50-58 Year: 2011
The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007